You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Low-Cost, Regenerable Air Filter for Efficient Gaseous Pollutants Removal
SBC: PRECISION COMBUSTION, INC. Topic: DPrecision Combustion, Inc. (PCI) proposes to develop a regenerable, low-cost, high-efficiency pollution control technology for removal of gaseous pollutants from contaminated air streams. This innovative air filter technology will combine our novel proprietary Microlith® support elements with sorbent nanomaterials that can be tailored to capture a variety of targeted gaseous pollutants. Originall ...
SBIR Phase I 2014 Environmental Protection Agency -
Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; however, there is currently no cure for the disease. Discovery that a naturally occurring variant of CCR5, the delta32 mutation, renders cells resistant to HIV infection has led to efforts by several a ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Formulation of LbL microparticle vaccine in microneedle array for intradermal del
SBC: ARTIFICIAL CELL TECHNOLOGIES INC Topic: NIAIDAbstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via layer-by-layer (LbL) fabrication of synthetic microparticles (MP). We have shown that LbL-MP loaded with epitope ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Endotoxin Neutralization as a Biomonitor for HIV Disease Progression
SBC: BIODTECH, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Endotoxin neutralization in human plasma is an excellent indicator of chronic immune activation, which is the most accurate predictor of mortality in HIV. Recently we developed an assay using endotoxin neutralization asan indicator of bacterial translocation. This assay is accurate in discriminating control patients from those with inflammatory bowel disease in ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New High Throughput Anti-Tumor Drug Screening System
SBC: Vivo Biosciences Inc Topic: NCIDESCRIPTION (provided by applicant): This SBIR project is focused to develop, validate and commercialize an advanced high-throughput anti- tumor drug screening platform (HTS) which employs a new 3D HuBioGEM assay technology. Preclinical drug screening is commonly performed using biochemical and cell-based assay systems. In recent years, more relevant 3D spheroid models have been developed using mi ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonists for Peripheral Pain
SBC: HALIMED PHARMACEUTICALS, INC. Topic: NIDADESCRIPTION (provided by applicant): Treatment of peripheral pain of various origins remains a major unmet medical need, affecting tens to hundreds of millions of people nationwide at some time during their lives. Kappa-opioid agonists have been shown in peripheral pain models to be particularly efficacious but suffer from centrally mediated effects that have limited their development. Perhaps the ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Engineered Neurotensin Fragments Targeting Neuropathic Pain
SBC: JT Pharmaceuticals, Inc. Topic: NIDCRDESCRIPTION (provided by applicant): Neuropathic pain management is a major unmet clinical need. Classically used medications, including opioids and non-opioids (primarily NSAIDs), have major side effects associated with their use, and many individuals donot respond to any medications. Neuropathic pain drugs with novel mechanisms of action are being sought as an alternative; however, the only succ ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Chronically Acting CFTR Inhibitor Discovery for Secretory Diarrhea and ADPKD
SBC: DISCOVERYBIOMED, INC. Topic: NIDDKProject Summary Abstract DiscoveryBioMed, Inc. (DBM) has launched an innovative and automation-friendly drug discovery program to screen a collection of small molecular compounds on a human epithelial cell platform expressing physiologically relevant levels of the wild-type Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) to discover a new class of therapeutic drugs for secretory disease ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a lasmiditan analogue for treatment of acute kidney injury
SBC: Mitohealth, Inc Topic: NIDDKDESCRIPTION (provided by applicant): The long-term goal of this project is to develop a safe and efficacious therapeutic small molecule for treatment of acute kidney injury (AKI). AKI results from diverse insults such as sepsis, ischemia-reperfusion (I/R)or nephrotoxicant exposure and nearly half of those who develop AKI do not survive. Since treatment remains largely palliative and survival rates ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Sterculic Acid Analogs to Inhibit Macular Degeneration
SBC: L2 DIAGNOSTICS LLC Topic: NEIABSTRACT The long-term product goal of this project is a small molecule therapeutic for choroidal neovascularization (CNV, the hallmark of wet age-related macular degradation), an abnormal growth of blood vessels in the choroid layer of the eye that results in damage to the retina and consequent blindness. Our lead compound is the natural product sterculic acid, which has been shown to inhibit ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health